WES: Whole Exome Sequencing Analytical Validation (MD Anderson)
BRD ID: 3,119
Source: CIMAC-CIDC Network Tier: SOP Number of times downloaded: 7
Description
This assay analytical validation and performance report describes the methods used to validate the Whole Exome Sequencing (WES) assay for the analysis of fresh frozen and formalin-fixed, paraffin-embedded (FFPE) tumor tissue and peripheral blood mononuclear cells (PBMCs). The document also presents data supporting the reported inter- and intra-assay reproducibility, concordance in mutation calls between FFPE and frozen specimens, reproducibility, and sensitivity and specificity. It is performed at the Cancer Immune Monitoring and Analysis Center (CIMAC) at MD Anderson Cancer Center. It is a product of the CIMAC and Cancer Immunologic Data Center Network (CIMAC-CIDC Network; https://dctd.cancer.gov/ResearchNetworks/cimacs_cidc_network.htm), a Cancer Moonshot Initiative.
Documents for Download
Analytical report_WES_10142019_MDACC_508r_Final.pdf [Size: 1382 KB]Biospecimens
- Tissue - Lung
- Cell - White Cells
Diagnoses
- Neoplastic - Carcinoma
Topics
- Analyte Extraction and Purification
- Platform-specific Methodology
Associated SOP Compendiums
- Analyte Extraction and Purification
- Platform-specific Methodology